Multiple MyelomaPhase 4MagnetisMM15NCT06057402
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
A Phase 4 study testing Elranatamab in people with Multiple Myeloma, run by Pfizer at 33 sites in 7 countries.
Trial summary
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Myeloma
- What is being tested?
- Elranatamab
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 33 sitesin 7 countries
- Study dates
- 3 Oct 2023to 22 Feb 2032
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants must agree to follow the reproductive criteria as outlined in the protocol
- Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).
Who cannot join
- Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.
Trial locations and contacts
33 sites in 7 countries. Contact the study team or a site near you to ask about taking part.
33 sites in 7 countries
United States17 sites, 17 recruiting
- Recruiting
University of Michigan
Ann Arbor, Michigan, 48109
- Recruiting
St. David's South Austin Medical Center
Austin, Texas, 78704
- Recruiting
Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center
Coral Gables, Florida, 33146
- Recruiting
University of Miami Hospital and Clinics Deerfield Beach
Deerfield Beach, Florida, 33442
- Recruiting
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)
Detroit, Michigan, 48202
- Recruiting
UCHealth Poudre Valley Hospital
Fort Collins, Colorado, 80524
- Recruiting
UCHealth Harmony
Fort Collins, Colorado, 80528
- Recruiting
UCHealth Greeley Hospital
Greeley, Colorado, 80634
- Recruiting
UCI Health - Irvine Infusion Pharmacy ACC
Irvine, California, 92612
- Recruiting
Longs Peak Hospital
Longmont, Colorado, 80504
- Recruiting
UCHealth Longs Peak Medical Center
Longmont, Colorado, 80504
- Recruiting
UCHealth - Medical Center of the Rockies
Loveland, Colorado, 80538
- Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida, 33136
- Recruiting
University of Miami Hospital and Clinics - Griffin Cancer Research Building
Miami, Florida, 33136
- Recruiting
University of Miami Hospital and Clinics
Miami, Florida, 33136
- Recruiting
UC Irvine Health
Orange, California, 92612
- Recruiting
UCI Health
Orange, California, 92868
China4 sites, 2 recruiting
- Active, not recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, 100191
- Active, not recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510555
- Recruiting
The first Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003
- Recruiting
Shandong Provincial Hospital
Jinan, Shandong, 250021
Australia3 sites, 3 recruiting
- Recruiting
Epworth Freemasons
Melbourne, Victoria, 3002
- Recruiting
Epworth Hospital
Richmond, Victoria, 3121
- Recruiting
Slade Pharmacy
Richmond, Victoria, 3121
Canada3 sites, 3 recruiting
- Recruiting
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5GN
- Recruiting
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
- Recruiting
McGill University Health Centre
Montreal, Quebec, H4A 3J1
Japan2 sites, 2 recruiting
- Recruiting
University Hospital,Kyoto Prefectural University of Medicine
Kyoto, 602-8566
- Recruiting
Japanese Red Cross Medical Center
Shibuya-ku, Tokyo, 150-8935
Spain2 sites, 2 recruiting
- Recruiting
Clinica Universidad de Navarra
Pamplona, Navarre, 31008
- Recruiting
Hospital Universitario Doctor Peset
Valencia, València, 46017
Taiwan2 sites, 2 recruiting
- Recruiting
National Taiwan University Hospital
Taipei, 10002
- Recruiting
Taipei Veterans General Hospital
Taipei, 11217
About this study
Official title: ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Read the detailed description
This is a single-arm elranatamab post-trial access study. Participants will receive elranatamab. All participants will receive elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination or, elranatamab becomes commercially accessible in the participant's country.
- Conditions
- Multiple Myeloma
- Being tested
- Elranatamab
- Keywords
- Multiple Myeloma, Elranatamab, Post Trial Access, Roll-over Study, Extension Study, MM-15, MagnetisMM15, BCMA, BCMA antibody, Magnetism, Bispecific antibody, Elrexfio
- Medical subject headings
- Multiple Myeloma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ElranatamabDrug
Also called Elrexfio
Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells
| Study group | Role | What they receive |
|---|---|---|
| Elranatamab | Experimental | Elranatamab is a heterodimeric humanized full length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells Receives: Drug: Elranatamab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of nonserious adverse events (AEs) leading to permanent discontinuation
Measured: A minimum of 90 days after the last dose of study drug
Incidence of serious adverse events (SAEs)
Measured: A minimum of 90 days after the last dose of study drug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2023
- Study start3 Oct 2023
- Primary completion22 Feb 2032 (estimated)
- Study completion22 Feb 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple MyelomaStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06057402
- Sponsor's protocol ID
- C1071015
- Other IDs
- 2023-505200-33-00, 2023
- Acronym
- MagnetisMM15
- Status last verified
- Jun 2026
- First submitted
- 5 Sep 2023
- Last updated
- 1 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
- ClinicalTrials.gov ID
- NCT06057402
- Acronym / sponsor ID
- MagnetisMM15 / C1071015
- Conditions
- Multiple Myeloma
- Keywords
- Multiple Myeloma, Elranatamab, Post Trial Access, Roll-over Study, Extension Study, MM-15, MagnetisMM15, BCMA
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 3 Oct 2023 (actual)
- Primary completion
- 22 Feb 2032 (estimated)
- Study completion
- 22 Feb 2032 (estimated)
- First posted
- 28 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Detailed description
This is a single-arm elranatamab post-trial access study. Participants will receive elranatamab. All participants will receive elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination or, elranatamab becomes commercially accessible in the participant's country.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Elranatamab | Experimental | Drug: ElranatamabElranatamab is a heterodimeric humanized full length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Participants must agree to follow the reproductive criteria as outlined in the protocol
- Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).
Key exclusion criteria (2 listed)
- Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ElranatamabAlso: ElrexfioElranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells | Drug | Elranatamab |
Primary outcome
Incidence of nonserious adverse events (AEs) leading to permanent discontinuation
Time frame: A minimum of 90 days after the last dose of study drug
Incidence of serious adverse events (SAEs)
Time frame: A minimum of 90 days after the last dose of study drug
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2026.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: No. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Multiple Myeloma
RecruitingPhase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Multiple Myeloma
RecruitingPhase 2
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
Multiple Myeloma
RecruitingPhase 1/2
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Multiple Myeloma
RecruitingPhase 1/2
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
RecruitingObservational study
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Multiple Myeloma, Lymphoma, Non-Hodgkin
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Pfizer CT.gov Call Center study director
Pfizer
33 sites in 7 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Elranatamab in people with Multiple Myeloma, run by Pfizer at 33 sites in 7 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 33 sites in United States, China, Australia, Canada, Japan and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pfizer CT.gov Call Center (1-800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of nonserious adverse events (AEs) leading to permanent discontinuation (time frame: A minimum of 90 days after the last dose of study drug). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.